BRPI0909096A2 - uso de conjugados de interleicna-1 no tratamento de diabetes - Google Patents

uso de conjugados de interleicna-1 no tratamento de diabetes

Info

Publication number
BRPI0909096A2
BRPI0909096A2 BRPI0909096A BRPI0909096A BRPI0909096A2 BR PI0909096 A2 BRPI0909096 A2 BR PI0909096A2 BR PI0909096 A BRPI0909096 A BR PI0909096A BR PI0909096 A BRPI0909096 A BR PI0909096A BR PI0909096 A2 BRPI0909096 A2 BR PI0909096A2
Authority
BR
Brazil
Prior art keywords
interleicna
conjugates
diabetes
treatment
Prior art date
Application number
BRPI0909096A
Other languages
English (en)
Inventor
Gunther Spohn
Martins Bachmann
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of BRPI0909096A2 publication Critical patent/BRPI0909096A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0909096A 2008-03-05 2009-03-05 uso de conjugados de interleicna-1 no tratamento de diabetes BRPI0909096A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152336 2008-03-05
PCT/EP2009/052639 WO2009109643A2 (en) 2008-03-05 2009-03-05 Use of interleukin-1 conjugates in the treatment of diabetes

Publications (1)

Publication Number Publication Date
BRPI0909096A2 true BRPI0909096A2 (pt) 2015-12-01

Family

ID=40839637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909096A BRPI0909096A2 (pt) 2008-03-05 2009-03-05 uso de conjugados de interleicna-1 no tratamento de diabetes

Country Status (14)

Country Link
US (1) US20110318300A1 (pt)
EP (1) EP2265281A2 (pt)
JP (1) JP2011513369A (pt)
KR (1) KR20100135767A (pt)
CN (1) CN101959526A (pt)
AU (1) AU2009221114A1 (pt)
BR (1) BRPI0909096A2 (pt)
CA (1) CA2717108A1 (pt)
IL (1) IL207647A0 (pt)
MX (1) MX2010009640A (pt)
NZ (1) NZ587670A (pt)
RU (1) RU2010140443A (pt)
WO (1) WO2009109643A2 (pt)
ZA (1) ZA201005875B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
DE602007011727D1 (de) * 2006-02-09 2011-02-17 Alain Dibie System zur behandlung von läsionen an einer blutgefässgabelung
US8992928B2 (en) * 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
JP2013504539A (ja) * 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
WO2008037504A1 (en) * 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
NZ566971A (en) * 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
JP2009511545A (ja) * 2005-10-14 2009-03-19 ノボ・ノルデイスク・エー／エス Ｉｌ−１インヒビターを使用する糖尿病の治療

Also Published As

Publication number Publication date
AU2009221114A1 (en) 2009-09-11
WO2009109643A3 (en) 2009-11-05
ZA201005875B (en) 2011-10-26
KR20100135767A (ko) 2010-12-27
MX2010009640A (es) 2010-09-28
CN101959526A (zh) 2011-01-26
NZ587670A (en) 2012-11-30
US20110318300A1 (en) 2011-12-29
IL207647A0 (en) 2010-12-30
JP2011513369A (ja) 2011-04-28
CA2717108A1 (en) 2009-09-11
EP2265281A2 (en) 2010-12-29
WO2009109643A2 (en) 2009-09-11
RU2010140443A (ru) 2012-04-10

Similar Documents

Publication Publication Date Title
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
BRPI0821668A2 (pt) Uso
BRPI0919193A2 (pt) Uso de lipídeo, e, composição nutricional
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
EP2296593A4 (en) MEDICAL HEAD COVER
BRPI0916125A2 (pt) "dispositivo de tratamento"
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
EP2207803A4 (en) Cd9-specific human antibodies
BRPI0812991A2 (pt) Utilização de combustível melhorado
DE502008001632D1 (de) Karosserieaufbau
EP3381471C0 (en) PAIN TREATMENT
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
BRPI1011417A2 (pt) uso de malonatos de benzilideno, preparação cosmética,e, malonatos de benzilideno.
BRPI0909096A2 (pt) uso de conjugados de interleicna-1 no tratamento de diabetes
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
HRP20160577T1 (hr) Liječenje osteoartritisa
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
PT3133396T (pt) Métodos de tratamento utilizando fármacos eliminadores de amoníaco
BR112012001837A2 (pt) uso de fulvestrant

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.